Finally, the results of a recent phase 1 clinical trial of the humanised anti-CD26 mAb YS110 in patients with mesothelioma, renal cell carcinoma and urothelial carcinoma CD26-expressing tumours showed a favourable safety profile and encouraged disease stabilisation in a subset of patients52. Here, DPP4 is linked to hereditary clear cell renal cell carcinoma.